vaccine-preventable subject free possible current such assert subsequent additional digital re-hosted educational non-commercial computer-extracted Computer-extracted such unusual odd Original 2021-11-05 Vaccine-PreWentable responsible additional Vaccine-Preventable commercial responsible current upper critical first Greek other 5th medical Vaccine-Preventable Other other Other live hacterial viral human lable Clinical live bacterial toxoid lable influenza human lable Other oral global lable last indigenous last wild lable flesponse Clinical 2005-2006 Immunocompromised recombinant Two-dose civilian lable C-1 ...... Vaccine-Preventable 1950-2003 1962-2004 ................ 272:1133-7 lable I-1 |-2 1-3 |-4 local Related current acellular single-dose acellular single-dose vial acellular single-dose acellular single-dose vial acellular single-dose | single-dose vial single-dose acellular single-dose acellular single-dose generic 10-dose generic 15-dose | single-dose single-dose | single-dose dose single-dose vial single-dose single-dose immune single-dose single-dose vial formulation- single-dose single-dose neonatal |- single-dose single-dose intranasal single-dosesymge dose vial single-dose – single-dose single-dose vial single-dose single-dose single-dose single-dose – single-dose single-dose vial 7-valent single-dose Pneumococcal 23-valent single-dose 5-dose vial single-dose 10-dose | single-dose generic 625-unit || multi-dose Japanese single-dose vial single-dose vial single-dose immune single-dose dose live oral Yellow single- 5-dose 521-7468 Vaccine-Preventable detailed basic useful Many available additional indigenous foreign infectious foreign specific single basic active passive own permanent human effective few complex primary foreign “ such immune specific cell-mediated foreign effective live alive such Other such long certain effective good infectious specific single own permanent other important human other temporary common last full-term same certain red small intravenous large whole red major homologous homologous human heterologous human many different many different high high other lesser several available human polyclonal many different single single antibody-producing specific single single related many certain colorectal ovarian chronic lymphocytic non-Hodgkin infectious available syncytial other other other specific other monoclonal general infectious many certain many antigen-specific cellular passive temporary active many similar natural active natural active similar natural similar natural viral bacterial protein-based polysaccharide-based wild effective similar natural effective more similar better Many maternal such nutritional basic live different live available live available whole Fractional protein-based polysaccharide-based bacterial Most polysaccharide-based wild serial wild small immune live ineffective such wild much milder natural adverse identical natural wild effective severe certain human original disease-causing live oral transplacental poor sensitive fragile available live viral yellow live available new live oral possible yellow oral oral available live 3-5 humoral available available pneumococcal meningococcal pneumococcal fractional polysac- alive entire live present antibody-containing general protective protective second third natural humoral cellular periodic supplemental available inactivated whole viral whole whole available available human available certain available pneumococcal meningococcal available immune independent able T-cell—independent immunogenic younger most inactivated “ functional polysaccharide little late independent pneumococcal meningococcal genetic available immunogenic functional thorough common more American current familiar important appropriate Specific antibody-containing live simultaneous nonsimultaneous different subsequent same antibody-containing live nonsinultaneous different subsequent same immune same certain such other immune parenteral live parenteral viral live necessary least necessary necessary antibody-containing live low anti-Rho rubella-susceptible other last possible necessary few immune significant live available syncytial young intravenous human other human live monoclonal syncytial decreased adverse eligible important appropriate early unvaccinated vaccine-eligible same same same different live parenteral less second effective yellow live other live parenteral live < second single-antigen yellow yellow oral oral oral other other available likely same live live oral oral oral live other inactivated live other multidose multidose youngest Most more adequate same optimal Table minimal minimal multidose necessary up-to-date international minimum minimum minimal earlier minimal younger minimum minimum older second consid- few minimum unlikely negative recommended reliable preferable reliable preferable valid 4-day minimum valid invalid greater certain local specific 4-day next significant final necessary available recom- necessary oral typhoid oral four-dose more long-lasting single multiple periodic additional single second immune second “ live long-lasting necessary recommended protective second third few notable periodic additional rare older active specific adverse extraneous primary extraneous adverse adverse true true adverse general local systemic least severe frequent least frequent common adverse local such Local common such Local few mild self-limited rare local severe due high many common unrelated concomitant viral unrelated adverse frequent whole-cell com- systemic adverse common acellular such º similar mild natural common self-limited due serious adverse adverse live mucous nose upper influenza-like third severe anaphylactic other such antibiotic bacterial allergic life- allergic good prior public private significant adverse significant adverse adverse Most temporary serious adverse adverse true serious general similar serious such passive less general present adverse high acellular pediatric high adverse few true severe anaphylactic due identifiable pediatric pertussis-containing greater shock-like hypotonic inconsolable more temporary live temporary severe recent antibody-containing severe allergic due identifiable severe anaphylactic medical severe urticaria appropriate allergic common animal yellow able anaphylactic anaphylactic-like adverse reasonable yellow influenza severe severe Egg-allergic prior anaphylactic neomycin allergy delayed-type cell-mediated delayed-type liquid commercial responsible allergic natural dry natural natural natural same lesser medical other natural vial intravascular synthetic medical vial synthetic natural natural allergic common contact-type latex-containing injection-procedure—associated diabetic anaphylactic natural other anaphylactic dry natural natural pregnant theoretical fetal theoretical pregnant pregnant Susceptible pregnant severe due uncontrolled oral live isolated safe • > alternate-day short topical significant immunosup- congenital immunosuppressed same live least large more prednisone more weight such alternate-day short less high-dose topical live human immune therapeutic monoclonal other opportunistic live live poor functional immunosuppressed human immuno- general same other severe asymptomatic severe due hematopoietic neoplastic own autologous other transplant vaccine-preventable autologous certain vaccine- preventable inactivated influenza immunocompetent meningococcal pneumococcal other available peripheral umbilical annual immunocompetent meningococcal small multiple prior adverse adverse severe live inactivated common such upper certain true Such common invalid minor anaphylactic certain mild such low-grade upper Several large young large small such mild Low-grade necessary immune antibiotic antiviral live-virus ill adverse critical healthy healthy live pregnant immunosuppressed noncommu- nicable human common older eligible low passive vaccine-preventable maternal certain low chronological initial gestational likely older larger eneral unknown initial count- ed additional first premature chronological chronological stable consistent Non-Vaccine-Related available such true relevant adverse sudden hereditary first-degree immune potential same false-negative same more most routine available such available serious adverse difficult few necessary severe time-efficient generic Most familiar minor medical last open-ended previous additional such high immune immunodefi- oral last last pregnant pregnant healthy last immune live last few unreported pregnant pregnant American Red American 1-98 recom- American opportunistic hematopoietic Infectious American important public safe efficacious important appropriate essential high own Vaccine-preventable lowest wild-type continued vaccine-preventable low several possible new suboptimal sustainable crucial vaccine-preventable unprotected other such severe social economic physical many ultimate late better optimal suboptimal other lower older pneumococcal racial Low-income greater underim- inner varicella vac- second low important fewer consistent influenza older least Sustainable High one-time short-term necessary effective such other specific such low successful current most sufficient least iº unvaccinated up-to-date necessary high other low knowledgeable capable new public private diagnostic high public private governmental nongovernmental medical other specific effective high sustainable measurable personal governmental medical potential necessary appropriate personal Much personal critical medical essential several most healthcare accurate own actual flexible defined necessary representative appropriate next second same summary specific substantial effective personal critical sufficient high desirable variable effective single different different small longer-term new other other possible diverse final more own other individual successful other knowledgeable appropriate statistical educational educational other such informal local professional actual such electronic different face-to-face e-mail cost-saving last several public private Many federal other available periodic possible single overall single more private large private electronic previous previous basic individual various potential such specific such available available effective gradual consistent private substantial median up-to-date public private state- public private annual widespread powerful Other substantial certain other immu- complementary favorable vital medical electronic critical applicable legal such available available easy easy i accurate active medical —reflect current up-to-date new necessary complete accurate School-based public community-based primary quick such important new alternative available patient population-based computerized geographic complete medical single reliable enrolled accurate additional immuniza- individual geographic younger operational population-based age-group federal local key federal available powerful recom- pediatric likely reluctant likely positive true many necessary useful next additional Reliable —powerful likely –verbal verbal due due due due .. effective effective various available computer-generated weekly other preventive other aggressive overdue local technical public private due due due due different overall —computer-generated computer-generated due such “ eligible several many simultaneous injectable immune adverse scientific available missed larger well-child Other large institutional bureaucratic such many different nonphysician direct such other positive simultaneous additional responsible knowledgeable responsible higher general available professional greater effective other knowledgeable valid additional appropriate immu- unknown physical psychological such specific such clinic many possible knowledgeable such eligible important such knowl- reliable direct supportive encouraging critical provider-based American high public public clinic cover- underimmunized cost-effective underimmunized private reg- prime general such potential specific significant public pharmaceutical safe effective adverse minor self-limited rare serious key active vaccine-preventable same adverse true adverse current vaccine-preventable likely adverse reportable vaccine-preventable public public critical decreased vaccine critical healthy lower rare sound several other similar willing vaccine adverse true unrelated public higher other medical pharmaceutical healthy healthy healthy lower sick possible rare adverse public many local widespread potential large universal human-directed strict regulatory dynamic necessary adjust oral global actual global continuous other pharmaceutical undergo human clinical clinical serious few last last several few several already-licensed adverse serious safe effective clinical rigorous potential outweigh common such injection-site small rare many largest inadequate possible rare essential vaccine-associated adverse public own public rare criti- cal particular high certain possible current postlicensure public ble rare large-linked rare specific vol- long-term unanswered clinical clinical individual certain adverse specific national significant adverse passive general local total large small additional unusual healthcare new rare patient significant medical certain local unknown adverse Serious adverse life-threatening serious additional medical full possible serious follow-up able primary new rare adverse patient particular adverse intussuscep- anaphylactic personal available 800-553-6847 common rare local systemic intrinsic recent adverse intrinsic individual vaccine-associated paralytic technical due natural More adverse plausible adverse specific clinical strong anaphylaxis natural positive clinical greater specific unvaccinated adverse other Large-Linked potential Such stud- informative costly time-consuming assess- single severe passive clear vaccine adverse high- active large-linked large computerized medical such single-provider such comple- adverse passive economical rapid medical more approxi- various available recent scientific indi- vidual certain adverse such similar regional infor- clinical vaccine individual Large-linked individual adverse better —vaccine prominent whole-cell scientific several vaccine public epidemic public certain adverse medical serious adverse certain available effective rare available federal key proper contraindica- available other possible Other expira- prescribed prior administra- same corrective available available important optimal same more spe- minimum • same important effective greater adverse serious adverse local dose unrelated medical such such pediatric serious adverse general present adverse Most temporary individual allergic American serious adverse most minor upper low-grade local moderate prior antimicrobial infectious unrelated best clinical vaccine anaphylactic available familiar cardiopulmonary certain adverse reportable available secure 877-721-0366 one-page 877-721-0366 valuable ongoing rare private available multiple legal understandable medical public private available responsible other available certain few certain religious personal basic devel- effective specific extensive up-to-date factual appropriate empathetic essential misinfor- available helpful effective public common unimmunized unimmunized certain potential vaccine-preventable unimmunized critical American permanent adverse current future new toxin-mediated 5th diphtheritic late aerobic gram-positive specific gram-positive genetic severe selective normal other nor- severe toxigenic responsible local responsible major low severe toxigenic inadequate 2-5 1-10 mucous mucous clinical -cutaneous —genital exudative 2-3 high anterior indistinguishable common blood-tinged white mild apparent poor systemic antibiotic common substantial systemic insidious low-grade bluish-white small soft greyish-green black minimal forcible Extensive severe rapid high severe submandibular anterior lymphadenopathy characteristic cutaneous common responsible high natural other recent nontoxigenic less other toxigenic Other mucous vulvovaginal attributable local abnormal cardiac early fatal soft frequent third fifth diaphragmatic Other due higher younger older little last clinical imperative presumptive critical tonsillar selective attributable local common hemolytic helpful clinical multiple club-shaped Other direct clinical diagnostic antibiotic positive presumptive low nonprotective commercial several available available 404-639-8257 other 770-488-7100. adequate provisional clinical appropriate maximum less contagious consecutive negative younger old old older 7- 10-day oral cutaneous non- clinical highest highest significant Native geographic asymptomatic high asymptomatic several 1940-2004 1980-2004 1980-2004 s 5-14 15-24 25-39 40-64 variable less more Effective antibiotic major top younger rapid widespread high cutaneous nontoxigenic cutaneous lower older older Most unimmunized immunized current inadequate many protective rare endemic classic toxigenic other major former More entire epidemic due several routine early early toxigenic available available pediatric available similar younger pediatric older pediatric available— 5-12.5 pediatric older 11-64 whºs first last Primary primary protective greater clinical acellular usual second third fourth third valid pediatric younger old first older first third second primary fourth fourth fifth recom- fourth fourth optimal last first least last dose next frequent local adverse older primary prior unvaccinated older primary first least third dose second first single unvaccinated older recommended subsequent active common self-limited palpable several other systemic common local diphtheria- tetanus-containing extensive painful severe high severe local severe systemic such severe allergic prior additional local systemic common systemic allergic severe minor additional cutaneous toxigenic appropriate preliminary clinical presumptive strict least negative close other oral close nasal antibiotic fewer unknown immediate pri- mary current more diphtheria toxoid-containing recent Other younger adequate antibiotic additional 10-day other preventive acellular young available due preventable former pandemic fatal character- convulsive skeletal 5th clinical fatal human same specific protective passive gram-positive anaerobic sensitive resistant usual other Manure-treated large agricultural significant human tetani clinical minimum human nanograms 70-kg gram-positive spore- human ng/kg unopposed i central nervous s 3-21 clinical local common rare common spasms 3-4 r- newborn protective passive low several central nervous peripheral spinal sympathetic nervous typical clinical unopposed autonomic nervous central nervous longer higher neonatal clinical different same anatomic many fatal rare ear present middle cranial facial common first trismus abdominal Other episodic rapid last several newborn protective unhealed umbilical unsterile common more rare vocal sustained nervous abnormal common Secondary hospital-acquired elderly common autopsied recent likely fatal older unvaccinated obvious direct clinical demon- foreign tetanic supportive adequate critical single available other last dose last contagious extreme practical useful proper important active passive primary tetanus clean minor uncertain early temporary protective encoun- populated hot organic intestinal major minor recent higher likely elective deep contagious vaccine-preventable infectious contagious early late late 1947-2004 notifiable ~0.05 recent all-time 1980-2004 older younger younger last younger younger older younger young injection-drug late 1980-2003 primary < 5-14 15-24 25-39 1991-1995 high 1991-1995 rare i recent available available frequent common Other insect other available other * 5-12.5 pediatric older 11-64 intravenous other chronic least primary injection-drug last fewer unknown prior formaldehyde-treated equal higher available single-antigen pediatric available Pediatric similar younger pediatric older pediatric available primary older younger greater minimal protective protective complete clinical last last rare last minimal protective small minimal protective other clean last fewer acellular usual second third fourth third valid pediatric younger old first older first third second primary fourth fourth fourth fourth first most last Primary 6-12 local systemic common systemic last least last dose next frequent local adverse older primary prior unvaccinated older primary first least third dose second single unvaccinated older recommended subsequent small active Adverse adverse common self-limited palpable several other systemic common local diphtheria- tetanus- extensive painful severe high severe local such generalized few peripheral neuropathy recent available brachial rare additional severe allergic useful appropriate severe routine minor toxoid-containing other clean pediatric severe acute American other preventive acellular young available //www.cdc.gov/nip/recs/provisional_recs/default.htm preventable high-risk neonatal infectious 20th common major more widespread more major small aerobic gram-negative fastidious special multiple antigenic active filamentous responsible clinical subsequent clinical Recent permanent toxin-mediated pulmonary recent present alveolar epithelial contagious gram-negative active filamentous 7-10 4-21 similar upper 1-2 cough 1-6 asymptomatic • insidious runny low-grade occasional similar common severe second paroxysmal paroxysmal numerous due thick tracheo- long characteristic high-pitched cyanotic young ill normal first same paroxysmal younger gradual paroxysmal subsequent many minimal asymptomatic present classic uncommon recent older other susceptible unimmunized underimmunized Older first multiple highest pertussis- common pertussis-related secondary bacterial younger such common Other serious severe subdural rectal encephalopathy pertussis-related younger younger such urinary characteristic physical useful young atypical preferred positive fastidious difficult direct successful posterior selective antibiotic effective trimethoprim-sulfamethoxazole first rapid sensitive available certain bacterial antimicrobial molecular 1-y 5-9 20-y useful nasopharyngeal low variable useful clinical difficult available clinical serologic national white present classical lympho- greater More available medical supportive communi- antibiotic effective such trimethoprim-sulfamethoxazole younger four-dose minimal first minimum dose minimum dose second human important respiratory airborne silent little distinct seasonal communicable secondary susceptible infectious cough Secular common 6-year reported annual fewer ~ catarrhal largest clear highest average annual younger * younger recent older annual older demographic detailed informa- many useful epidemiologic highest greatest severe recent available current clinical least inspiratory posttussive other apparent clinical laboratory-confirmed compatible clinical appropriate endemic sporadic outbreak least other Vaccine-Preventable available probable formalin-inactivated clinical subsequent observational primary whole-cell effective serious little last Local such other mild systemic common severe systemic such hypotonic such develop- more purified adverse 5-10 common full 59-90 inactivated Several acellular different different available fourth fifth pediatric available sanofi equal available 2-phenoxyethanol single-dose available pediatric similar pediatric same single-dose several effective acellular effective whole-cell local systemic serious such high hypotonic acellular various pediatric single similar new similar clinical similar available 4- 8-week fourth third other indicated fourth certain fourth fourth least least third unlikely additional fourth 15-18 15-18 15-18 17-20 primary fourth dose necessary fourth primary fourth fifth whole same possible limited same possible available available different necessary acellular eligible primary single different single single single single 5-year local systemic less adverse such younger young single single single recent toxoid-containing single least close infant younger shorter last recºnd- ose toxoid-containing necessary pregnant single close single recent toxoid-containing least close immediate pregnant single same other permanent single least such diphtheria-containing first available older primary available separate other single acceptable primary fourth more primary age- valid primary final least last prior least prior protective least high separate fourth younger fourth fifth other pertussis- necessary same possible positive Other neurologic possible potential prolonged certain neurologic uncontrolled progressive other neurologic stable neurologic idiopathic cerebral other pertussis-containing necessary positive unknown neurologic neurologic g additional —typical clinical culture-proven severe adverse common common * 5th full multiple smaller altered significant likely full smaller standard additional typical clinical such other other other certain local such frequent fourth systemic such low-grade common higher whole-cell self-limited severe such higher febrile persistent last- longer hypotonic hyporesponsive common fewer comprehensive adverse full Available substantial local fourth fourth fourth other systemic supplemental state- entire upper certain acellular substantial local self-limited entire fourth extensive fourth fifth fourth fourth improved whole-cell common adverse local such low-grade nonspecific such gastrointestinal same acellular serious adverse adverse entire Low-grade same acellular identifiable severe higher other identifiable shock-like hypotonic inconsolable > allergic identifiable pertussis-containing previous toxoid-containing neurological severe local prior severe allergic due identifiable severe vaccina- such upper severe acute adverse subsequent higher due identifiable shock-like inconsolable longer communitywide precautionary adverse additional severe encephalopathy due identifiable pertussis-containing previous toxoid-containing progressive such uncontrolled severe local prior toxoid- least last Td-containing severe severe certain such higher persistent subsequent adverse stable such controlled cerebral American young antimicrobial anti-vaccine untold acellular spinal spinal compatible recognizable first early next severe average older paralytic effective last wild-virus global eradica- next transient gastrointestinal stable small ether-insensitive minimal significant other ultraviolet primary multipli- gastrointestinal several local blood- central nervous anterior typical ultraviolet local central nervous non-CNS variable clinical asymptomatic paralytic able minor nonspecific clinical laboratory central nervous clinical abortive complete less poliovirus upper gastrointestinal abdominal indistinguishable other viral aseptic several similar last complete normal biphasic initial minor 1- major superficial deep asymmetrical most present permanent common paralytic most cranial spinal paralytic cere- brospinal diagnostic genomic wild high fourfold white wild endemic possible 7-10 3-6 inapparent asymptomatic immune fecal-oral important oral-oral seasonal tropical infectious susceptible greater susceptible infectious present Secular Initial least early maternal high continual paralytic immediate frequent primary natural susceptible paralytic early oral paralytic last paralytic endemic wild several paralytic last imported recent direct vaccine-associated paralytic live oral last unvaccinated several asymptomatic vaccine-derived unvaccinated least genetic early other first available monkey 2-phenoxyethanol single-dose subcutaneous intramuscular 1950-2004 1980-20 effective • effective dose monkey single intestinal viral first fecal effective protective least immune paralytic local wild many complete effective single more other live-virus oral lifelong excellent intestinal lower low fourth fourth similar other exclusive paralytic sequential occur- vaccine-associated paralytic sequential humoral inactivated third fourth sequential complete complete complete paralytic available indigenous primary other first early second third 1996-1999 sequential paralytic available whºs 6-18 fourth early first second necessary immune third high preferred second third minimum minimum fourth fourth fourth fourth third fourth adminis- i fourth specific fourth necessary available routine available complete minimum • 4-6 complete 5-component same younger fourth fourth necessary immune small polio-endemic endemic epidemic eastern close wild specific current wild previous available unvaccinated prior third available available least available single P- increased further supplementary supplemental complete necessary additional endemic full last necessary possible 1-2 6-12 separate complete local serious available paralytic 5-10 exclusive Most healthy Vaccine-Associated local serious adverse docu- strepto- allergic Vaccine-Associated paralytic rare adverse live oral live paralytic identical permanent likely immuno- normal higher certain available paralytic older paralytic healthy average Forty- healthy average immunologic abnormal equal other overall normal overall first other able revertant similar last allergic further allergic anaphy- lactic such severe successful upper local prior current antimicrobial con- same individual clear Last • free Last preliminary clinical paralytic appro- local appropriate viral single paralytic immediate vaccine-associated unvaccinated epidemic older uncertain widespread many paralytic more fewer last indigenous wild acute flaccid such national last wild-virus—associated indigenous additional intensive international free indigenous detailed national global substantial last international other bilateral multilateral Current global available paralytic new new syndrome permanent residual paralytic infectious more postpolio Post-Polio 63.108-2915 3.14-534-0475 wild global global last indigenous wild virus-associated new paralytic severe clinical secondary unencapsulated capsular cerebrospinal effective bacterial other invasive bacterial younger invasive younger younger influenzae gram-negative aerobic facultative dinu- polyribosyl-ribitol responsible distinct capsular invasive influenza influenzae gram-negative different a-f invasive several asymptomatic normal common upper invasive exact unknown striking age-dependent common capsular protective invasive ug/mL unconju- long-term invasive anticapsular age-specific asymptomatic small common antigenic so-called anticapsular other genetic important genetic unknown single genetic many organ common invasive common clinical invasive pre- other other neurologic appropriate antimicrobial life-threatening focal severe common invasive common invasive due nontypeable unencapsulated invasive rare serious common small gram-negative invasive pleural middle appropriate positive ºr-tº- neurologic effective antimicrobial effective Ampicillin-resistant common higher important younger vaccine influenzae antimicrobial viable available rapid sensitive specific capsular negative false-positive similar aggluti- sensitive difficult invasive effective chloram- Ampicillin-resistant common life-threatening etiologic initial empiric out- asymptomatic primary seasonal second contagious invasive certain particu- close institutional direct secondary reportable Serotype-specific incomplete national several active younger popu- invasive invasive younger invasive Three-hundred due unvaccinated age-dependent invasive older invasive invasive younger young 1990-2004 199- 0-1 12-13 24-25 36-37 48-49 recent unvaccinated three-dose primary Fifty-six eligible primary age-eligible fewer unknown younger invasive due unknown actual vaccinated large house- low socioeconomic low parental school-aged socioeconomic chronic socioeconomic –low higher -chronic younger maternal invasive secondary 600-fold higher general popu- younger older secondary first second third fourth secondary trans- Most low secondary effective younger older negative greater available similar other polysaccharide pneumococcal meningococcal typical T-independent age-dependent poor younger minimal polysac- ineffective effective T-independent T-dependent young class-specific useful first immunogenic available young different available 1985-1988 effective older variable immunogenic old functional young utilize different available young protective primary uncommon invasive such sickle-cell human invasive primary separate primary primary three-dose primary primary ACIP-Recommended primary minimum least interval previous primary second third simulta- other primary immunologic immunologic subsequent younger interchangeable protective necessary primary older full current interchangeable primary dose influenzae entire current 15-59 least 2-6 ” dose dose 2-6 ” least previous least last least last single protective invasive high-risk least last child single up-to-date three- four-dose catch-up invasive protective anti-PRP invasive susceptible possible general older older immune asymptomatic older invasive functional anatomic sickle hematopoietic unvaccinated older least pediatric available available separate other single acceptable primary fourth more primary valid primary final least last prior least prior Hib-containing prior immune younger 0-1-6-month primary fourth prior same individual adverse adverse positive chronic same adequate off-label positive unknown same individual particular third older least second common such adverse local systemic similar concurrent individual serious adverse severe moderate severe upper younger immunologic same individual reportable healthcare invasive local American Red American invasive vaccine-preventable older influenzae invasive preventable acute viral infectious early Persian lifelong human live available immune common fatal single-stranded important responsible viral responsible antigenic important acidic short less systemic primary regional primary subsequent viral regional distal second initial other nasopharynx contagious viral universal fatal important light regional 2-3 5-7 10-12 higher * 5-6 confluent 1985-1992 charac- high mucous pathognomonic blue-white bright red buccal next downward discrete upper most involved same Other more common younger older viral bacterial common stiff residual many other higher young common rare degenerative central nervous due insidious progres- sive early higher spontaneous low-birthweight definable malfor- Atypical inac- pleural maculopapular petechial urticarial vesicular local severe immune young residual mild discrete short mucous certain lym- typical several high younger severe bacterial high important molecular epidemiologic clinical geographic viral urine nasopharyngeal public viral same likely more viral available enzyme-linked available diagnostic susceptible wild-type many negative negative positive previous single diagnostic positive other positive first false-negative negative first detectable least available indirect possible second speci- same same specific second indigenous other human asymptomatic large communicable greater secondary susceptible Secular epidemic actual More highest 2–3-year epidemic indigenous lowest annual school-aged younger younger first school-aged second dramatic 1950-2004 1980-2004 1975-2002 1989-1991 • I- school-aged largest younger first younger 5–19-year-olds highest lowest non-Hispanic higher non-Hispanic measles-associated death-to-case younger fatal largest annual important low low many large preschool-aged early experi- preschool-aged few second black likely white younger high other many young due wild smaller higher susceptible younger many other 1993-2004 low annual due preschool-aged 2-year-old fewer fewer low annual other other aggressive low older high many prior second school-aged school-aged uncommon preschool-aged More several more largest pre- school-aged last large largest religious personal largest large measles-related pre- preschool-aged older low due recent high aggressive large maculopapular probable gener- higher noncontributory probable clinical probable possible local international local indigenous indigenous available //www.cdc.gov.nip/publications/surv-manual/default.htm measles- Two-dose measles- Most live fre- unique atypical wild-type original high live fewer original available live available single-antigen individual freeze-dried sterile preservative-free small human noncom- municable approxi- similar primary other first first first serologic vaccine-induced lower natural serologic epi- demiologic vaccine-induced long-term Most vaccinated anamnestic available secondary successful minor least least other adoles- first first measles-containing least second first second first catch-up earlier first additional other acceptable minimum valid primary first second possible less first 12-15 4-6 first parental other acceptable permanent medical specific indicated other older medical i medical least measles- rubella- other acceptable pregnant medical acceptable special other post-high educational medical international other post-high educational potential high-risk large sus- ceptible technical other post-high other acceptable live other acceptable first prior other measles-containing first second least previous medical higher general least overall medical medical medical medical nonmedical full patient-care tible medical private public possible low live live second least first acceptable medical medical live last unknown unknown laboratory laboratory medical cost-effective susceptible necessary other acceptable timely endemic epidemic many other certain unvaccinated least first last unknown unknown neces- sary temporary maximum susceptible younger highest live passive susceptible adverse common adverse susceptible higher Most asymptomatic Measles- rubella-containing low susceptible temporal clinical greater higher thrombocytopenic other rubella-containing other other susceptible rare rare Most minor anaphylactic rare uncommon possible second independent nongovernmental American available current severe prior • anaphylactic serious measles- mumps- anaphylactic measles- other such serious allergic chick egg-allergic low skin-testing allergic i egg- allergic prior routine special severe other pregnant pregnant due large virus subsequent least immunocompromised susceptible immunocompromised general large more least high-dose low-dose short-course less alternate-day topical intra-articular high systemic component least severe severe unusual adverse severe immunosup- variable asymptomatic symptomatic other measles-containing theoretical other clinical such asymptomatic severe immuno- other measles-containing severe HIV-related Age-specific severe HIV-infected ul total severe acute ill potential such mild upper antibiotic other recent upper previous subsequent immune whole red intravenous immune such concen- intravenous thrombocytopenic significant direct vaccine-induced natural greater potential greater subsequent previous previous such other measles-containing same admin- measles-containing same measles-containing least theoretical least favored less less average less recon- stituted same first—give skin American Red American global fatal congenital health-care 54:1229-31 global autistic second acute viral filterable frequent military common aseptic common military same cross- single-stranded various human cerebrospinal ultraviolet respiratory regional such characteristic aseptic low-grade common infected unilateral bilateral single salivary first viral • military ultraviolet regional 12-25 14-18 low-grade asymptomatic many asymptomatic additional nervous aseptic common clinical inflammatory cerebrospinal post- higher absent many such rare * testicular common postpubertal many postpubertal bilateral abrupt last testicular rare ovarian infrequent reversible single many temporal few unilateral vestibular sudden compatible symptomatic rare Other less common clinical particular clinical clinical acceptable nasopharyngeal buccal buccal upper best viral buccal viral simplest available sensitive other available detectable first few possible symptom acute-phase human asympto- matic nonclassical airborne direct infected late —positive —significant active 1968-2004 | 1980-2004 1980-2003 similar infectious active reportable relative highest older routine comprehensive high single many many laboratory due complete appropriate many true early 5–9-year late older older urban suburban serologic clinical unilateral bilateral self-limited other other apparent short-lasting live available single-antigen measles-mumps-rubella individual freeze-dried sterile preservative-free small human noncom- single measurable similar single vaccine-induced greater lifelong vaccine least mumps-containing first mumps-containing unilateral bilateral self-limited other salivary other first Mumps-containing least second first first second second available first second second dose long- available second first adolescent catch-up medical least least measles- rubella- other acceptable high second valid Self-reported parental other acceptable permanent medical specific indicated other older immune physician-diagnosed live first acceptable “ equivocal susceptible Live 5- likely recognizable arbitrary necessary immune effective harmful adverse such joint attributable compo- adverse large-scale adequate rare rare allergic severe chick allergic few vaccine evi- inadequate aseptic sensorineural severe allergic prior anaphylactic serious measles- mumps- anaphylactic measles- other such serious such egg-allergic low skin-testing predictive allergic egg-allergic prior routine special theoretic immune immunosuppressive low-dose less alternate-day topical immunosuppressive additional human severe mild upper antibiotic other antibody-containing immune whole red intravenous immune serocon- least antibody-containing less refrig- average American relative vaccine- preventable little red “ third separate medical common “ German viral viral acute little red variant distinct clinical German widespread Australian congenital maternal early first such eastern western single other unstable lipid low low regional mitotic regional 5-7 subclinical first rare older lymphadenopathy upper maculopapular 14-17 12-23 low-grade 14-17 second pruritic hot last several posterior cervical many integral Other soft diagnostic common rare same last chronic rare secondary low thrombocytopenic common cerebral intrarenal last Additional late progressive 1964-1965 main surgical/spontaneous emotional disastrous early fetal spontaneous many first fetal rare overall third greater uncomplicated common sole congenital espe- fourth includ- such ventricular possible mental other progressive older low high many subclinical reliable acute positive viral rubella-specific significant acute- fetal spleen clinical serologic urine cerebrospinal diagnostic viral intensive many routine valuable epidemio- viral common significant acute- possible False-positive positive infectious positive available available preferred Enzyme-linked sensitive available easy diagnostic sensitive fourfold greater diagnostic recent rubella-specific primary rapid sensitive available false-positive due human animal true airborne trans- insect subclinical asymptomatic highest contagious contagious more large susceptible Secular notifiable largest annual fewer moderate due low annual independent available careful longer • late 5-7 1966-2004 younger older 1980-2004 young largest annual due susceptible young Most reported foreign-born most Latin American most clinical generalized maculopapular higher lymphadenopathy recent maculopapular lymphadenopathy 1980-2003 generalized probable clinical virologic laboratory-confirmed laboratory clinical laboratory-confirmed congenital congenital peripheral pulmonary pigmentary developmental infection-only clinical compatible clinical probable probable other consistent probable eye-related single compatible higher joint human other live rubella-infected aborted human fibrob- communicable available nonpregnant individual i single-antigen freeze-dried sterile preservative-free small human safe immunogenic older serologic single More vaccinated clinical least Follow-up long-term lifelong similar single-antigen Several low detectable unknown uncommon clinical fetal vaccine-induced pregnant least least first first rubella-containing least second first second second available first second second dose long-term available second first first second first older least medical least least measles- rubella- other acceptable high second susceptible valid Self-reported parental other acceptable permanent medical indicated other older immune least • other live rubella-containing first serologic equivocal serologic rubella-susceptible acceptable routine acceptable unvaccinated acceptable pregnant positive appropriate pregnant immune laboratory important pregnant detectable unreliable many many reliable previous reliable negative Such serologic medical cost-effective susceptible timely prior necessary other acceptable immune effective harmful adverse such attributable common lymphadenopathy adverse common rare rare susceptable arthritis-like Population-based severe such joint susceptible susceptible susceptible postpubertal acute arthritis-like transient peripheral neuritic such acute other chronic seronegative seronegative unimmunized neuropathy severe allergic prior pregnant pregnant fetal next immune immunosuppressive low-dose less alternate-day topical immunosuppressive asymptomatic symptomatic severe mild upper con- current antibiotic other antibody-containing immune whole red intravenous immune serocon- least adminis- antibody-containing necessary Previous human immune contraindi- anti-Rho immune serologi- serious pregnant pregnant likely pregnant next pregnant other theoretical pregnant likely next theoretical 1971-1989 routine pregnant pregnant pregnant such subclinical susceptible susceptible vaccine-induced maximum theoretical low routine small theoretical pregnant refrig- average low several high indigenous susceptible young premarital possible at-risk special supplemental susceptible immune important susceptible American American pregnant congenital rubella-containing congenital preventable infectious Primary infectious vesicular vesicular healthy other first latent regional other such sensory secondary viral varicella viral regional sensory 14-16 10-21 1-2 2-4 pruritic pruritic highest centripetal mucous superficial clear erythematous several present several macular same successive clinical healthy severe higher gastroin- severe progressive high extensive vesicular high prolonged primary healthy second common other viral natural wild clinical detectable young younger immunocompromised skin central nervous pulmonary hepatic extramedullary cranial Most fifth cranial few systemic available last other severe mild self-limited common secondary bacterial skin central nervous common outpatient medical serious viral bacterial Secondary bacterial common younger nervous aseptic common good rare • cerebral common unusual unknown dramatic aseptic hemorrhagic clinical healthy < 1-14 20-29 first small Most normal healthy older high serious high organ fulminant pneumo- high severe fetal passive maternal prior due passive maternal low muscular cortical first congenital primary maternal first low less Rare congenital maternal virologic maternal ear- exact unknown useful necessary atypical available adverse wild-type such laboratory frequent vesicular wild-type severe unusual specific antiviral rapid clinical available specific available available several real-time unavailable direct sensitive meticulous fresh fluid-filled Other such nasopharyngeal bronchial desirable skin positive such likely viral viral positive viral negative reliable valid distinctive subclinical unusual necessary useful available Available indirect indirect hemag- immune latex enzyme-linked sensitive specific available available sensitive rapid sensitive commercial false-positive useful lower Commercial sensitive vaccine-induced potential false-negative routine significant standard commercial available false-positive common high reli- able 404-639-0066 404-639-3667 common distri- i 1-2 4-5 rural human insect common tract secre- airborne direct acute distinct seasonal highest early highest lowest tropical seasonal first contagious entire new contagious contagious more Secondary susceptible high Secular endemic adult- notifiable younger highest age-specific earlier older active varicella-related i 1990-1994 1-4 5-9 to-14 15-19 1-4 5-9 10-14 15-19 active notifiable Ninety-five first least live attenuated viral early healthy general sequential embryonic embryonic small residual live attenuated identical equal higher plaque-forming = detectable More least Japanese moderate severe effective effective severe healthy second least second first clinical antigenic clinical healthy single similar separate long-lasting fewer fewer many Most recent younger younger several impotent inaccurate live viral long-lasting unvaccinated consistent 2.5-fold higher less more more 12-18 necessary reliable reliable chick- susceptible severe simultaneous first second first second such equivalent first eligible vaccina- safe effective healthy same separate separate same least separate separate other other reliable typical such clinical single least healthy detectable single older first second desirable higher highest likely older high severe high other reliable uncertain likely cost-effective necessary seropositive available commercial sensitive 4-8 susceptible • cost-effective necessary age-appropriate • typical —non-U.S. —all 1966-1997 full available clinical infectious other constitutional atypical susceptible low susceptible potential vaccine-associated high serious such age-appropriate parental typical non-U.S.-born atypical epidemiologic typical previous such valid other mild atypical effective subsequent prodromal vaccine-associated adverse post- preferred second outbreak second least older Adverse common such clinical local second local varicella-like effective effective maculopapular vesicular common Most vaccine less wild allergic Most immunocompromised humoral asymptomatic HIV-infected second present varicella-like second Most maculopapular live similar less wild-type such postherpetic similar other severe allergic due immune immunosuppressive low-dose less alternate-day topical immunosuppressive cellular isolated humoral severe cellular asymptomatic symptomatic age-specific higher 3-month impaired cellular greater common live pregnant pregnant adverse insert American prenatal post- second other maternal—fetal pregnant 800-986-8999 severe ill potential such such upper antibiotic other active lower * antibody-containing immune whole red intravenous unknown potential antibody- same antibody-containing additional such least antibody-containing seronegative secondary few secondary clinical secondary wild several asymptomatic high such fragile frozen average frost-free low acceptable unsealed uninsulated small dormitory-style combi- capable preservative other antiviral short separate 800-9WARIVAX 800-982-7482 short possible central off-site difficult off-site dry appropriate average 3-4°F -20°C average onset —susceptible pregnant human high available 800-843-7477 clinical negative likely impor- greater general expensive temporary high significant continuous hospital same 2- 4-bed direct neoplastic immunosuppressive less gram adequate maternal immune such congenital postexpo- pregnant possible longer detailed available //www.cdc.gov/nip/publications/acip-list.htm 625-unit last early severe severe available intravenous best anti-varicella clinical available neonatal less less neonatal pregnant possible effective late comparable recommended antiviral significant first last last strict entire longer i Several antiviral active beneficial new cutaneous systemic specific initial antiviral American routine antiviral healthy healthy severe cutaneous pulmonary long-term short intravenous possible uncomplicated oral pregnant second third American other provisional updated Available varicella- healthy first epidemic military infectious definitive other non-B primary hygienic passive immune long-term widespread natural several nonhuman stable stable low moderate higher fecal-oral present biliary present several clinical infected third longer * natural low high 10-12 15-50 specific symptomatic asymptomatic symptomatic clinical indistinguishable other acute viral abrupt abdominal last symptomatic younger asymptomatic older symptomatic fulminant higher older older substantial medical ill direct indirect pediatric annual other viral clinical detectable anti-HAV early anti-HAV detectable Anti-HAV present total anti-HAV anti-HAV anti-HAV total anti-HAV positive anti-HAV such viral helpful investi- molecular supportive endemic natural animal chronic fecal-oral person-to-person present rare present sewage-contaminated treated appreciable seasonal likely highest minimal personal sexual recent international Injection-drug Forty-five international illegal occupational fulminant solvent/detergent-treated noteworthy critical foodborne nosocomial rare neonatal intensive fecal developmental high fewer sporadic common common work-related available important asymptomatic unrecognized other large last high reportable largest low annual symptomatic low highest early similar anti-HAV general 6–11-year-olds older Anti-HAV highest Anti-HAV higher western other western Many high- late similar Many such high-rate intermediate-rate last several substantial high few older well-defined 1966-2004 1990-2004 19-yrs 1990-2004 Overall whole seropositive seropositive seropositive seropositive certain religious high-rate high first-dose young subsequent clinical other viral clinical serologic necessary clinical discrete positive anti-HAV available human preservative 2-phenoxyathanol available pediatric older younger protective single seropositive first clinical effective clinical clinical high clinical high long-term immune current available kinetic protective Other cellular long-term unknown postmar- international other little successful high routine older average annual higher least routine average annual more successful high routine subsequent 12-23 routine available single older 6-12 6-12 initial subsequent initial available pediatric pediatric dose older deltoid 6-18 6-12 initial subsequent initial 6-18 first dose 6-18 first different interchangeable same preferable available acceptable first first pediatric first necessary first immuno- adverse same other Similar equivalent pediatric equivalent three-dose long-term first third least first second least second third least necessary older equivalent same single-antigen least second single-antigen pediatric older high first second dose necessary long-term available * illegal complete initial occupational different anatomic younger younger i high-risk Other other illegal occupational occupational A-infected other due occupational local Susceptible Susceptible solid routine local past such higher negative likeli- low cost-effective extensive geographic high older certain certain high available total high low anti-HAV diagnostic local mild self-limited systemic serious severe allergic vac- preservative 2-phenoxyethanol common serious adverse severe severe theoretical low uvith human negative effective administra- clinical large single possible more close sexual certain common-source HAV-infected transmis- high least injected live least least measles- mumps- rubella-containing live American active passive green several similar infectious early human specific first human early first complete serologic natural effective small double-shelled Other small circular double-stranded numerous nonhuman resilient infectious environ- least * antigenic least common infected chronic hepatocellular second human hepatocellular chronic chronic Several well-defined hepatitis-associated antigenic subviral 22-nm spherical variable infectious complete infectious present complete detectable conventional soluble high high anti-HBs acute anti-HBs potential undefined recent anti-HBe detectable low clinical indistinguishable other acute viral 60-150 average average Clinical asymptomatic specific least asymptomatic asymptomatic prodromal initial insidious quadrant abdominal icteric variable gray hepatic common other acute complete anti-HBs acute complete fulminant severe serious due chronic chronic chronic many most i Higher early chronic asymptomatic i responsible HBV-related chronic active more estimated B-related 1-6 7-12 1-4 5-yrs higher clinical epidemiologic clinical definitive early infectious chronic serologic acute anti-HBc recent detectable best serologic negative positive single chronic due due natural 1-2 immune sensitive low susceptible false positive undetectable useful infective higher protective anti-HBs positive appropriate milli-international protective supportive effective chronic successful other infective other other insect parenteral highest serous lower other such other unlikely 1-2 important transmis- sexual heterosexual homosexual Fecal-oral asymptomatic percutaneous injection-drug important other percutaneous other sharp medical small needle such fresh cutaneous other infective other direct mucous such hand-to-mouth hand-to-eye infective infective mucous environmental various other positive positive infected positive many positive vary different global high HBs.Ag-positive moderate HBs.Ag-positive low less HBs.Ag-positive global common global global most greater early chronic greatest most asymptomatic little acute high low low infectious present present reportable many reportable distinct serologic different available early injection-drug greatest acute new additional acute approxi- perinatal chronic 1978-2004 common sexual heterosexual early widespread uncommon uncommon general prevalent certain ºc- highest infected frequent chronic high-risk i injection-drug high 35-80 illicit parenteral 60-80 active 35-80 3-10 20-80 3-6 30-60 1-8 10-80 frequent 1-2 15-30 multiple 5-20 † 3-10 first-time available apparent uted several high large major infected multiple injection-drug immuniza- effective public private high-risk rapid high-risk low initial low comprehensive pregnant perinatal routine high plasma-derived 22-nm human safe effective unsubstantiated other human first recombinant second similar high-risk plasma-derived common • i yeast-derived final infectious viral complete viral pediatric available pediatric different interchangeable two-dose pediatric pediatric younger Engerix-B preservative residual other single healthy more adequate age-specific three-dose protective anti-HBs higher less * immune effective clinical complete normal protective high necessary other 40-mcg special ug ug ug ug 1-10 11-15 11-19 other immunocompromised 2-dose 3-dose more immunogenic specific * 4-dose anterolateral lower least inch least inch other anterolateral valid Available vaccine-induced more • significant clinical anamnestic anti-HBs significant anamnestic significant normal immune additional available annual younger pediatric 1-2 intramuscular usual positive unknown third highest last least preferable 2-month other good appropriate difficult vacci- third least second first least third earlier necessary longer HBs.Ag-positive unknown less chronologic initial gestational likely full-term low negative first stable full available same pediatric equivalent individual other younger potential positive unknown least first positive chronologic negative positive unknown first 5-component least high fourth younger fourth fifth other pertussis- necessary same other pertussis-containing necessary possible f total positive positive unknown unknown [ 11-19 age-appropriate routine local deter- young highest flexible possible Asian active pediatric usual third dose minimum first minimum second third first third less minimum alternative alternative 10-mcg anti-HBs similar 5-mcg alternative 2-dose older pediatric usual less third dose minimum first minimum second third first third less minimum necessary third first least Alternative sexual other * multiple Injection-drug high injection-drug suscep- tible possible long-term injection-drug homo- sexual other high-risk large effective susceptible percutaneous permucosal public such highest other allied equivalent pediatric equivalent three-dose long-term first third least first second least second third least necessary older equivalent standard same Other special behavioral medical high-risk other infected present certain such such important susceptible susceptible younger high unaccompanied high positive susceptible anti-HBs positive positive close local sexual local common medical common high Other unaccompanied high certain high routine high —immunodeficient certain such high specific casual such special such medical severe potential immune cost-effective high higher such injection-drug endemic-disease HBs.Ag-positive cost-effective low such routine such suboptimal such HBs.Ag-positive necessary HBs.Ag-positive final third fourth present anti-HBs present comprehensive sharp catch-up necessary significant low such public direct Several older primary additional additional first second three-dose second usual 6-month 4-month healthcare second detectable anti-HBs anti-HBs negative low detectable positive three-dose negative susceptible second usual • 1-2 second anti-HBs.Ag valid probable parenteral HBs.Ag-positive difficult negative anti-HBs possible negative true initial detectable vaccinated detectable true second anti-HBs sixth second expensive single positive previous further serologic anti-HBs “ seronegative total same high anti-HBs anti-HBs passive accidental percutaneous mucous sexual HBSAg-positive younger old primary Most high-risk cold low low valid current unavailable high chronic effective pre- chronic effective same different available first second third first third other pediatric initial 3-dose next chronologic third second fourth unknown positive possible important second unknown maternal first different reliable additional available chronic HBs.Ag-positive off-label positive unknown younger same other older percutaneous needle unknown available positive unknown anti- necessary inadequate anti- adequate necessary inadequate 1-2 immune adequate anti-HBs inadequate anti-HBs second 3-dose susceptible single last sexual last sexual more late chronic anti-HBs chronic chronic unvaccinated first second second nonsexual infected common such Serious systemic adverse systemic rare neurologic newborn multiple British severe acute large population-based severe allergic Such allergic rare severe such upper inadvertent pregnant severe chronic pregnant eligible such suboptimal American comprehensive health-care occupational multiple neonatal infectious viral epidemic first epidemic least 20th “ Spanish inactivated protective single-stranded nuclear other wild Most pathogenic natural stable less antigenic immunologic human subclinical epidemic due sequential infectious viral least 1918-1919 other nuclear specific interpandemic serial irregular major antigenic protective new pandemic major due genetic antigenic pandemic last major prior wide geographic pathogenic avian person-to- necessary pandemic same similar epidemic predominant widespread last different much major pandemic single high greater individual large severe fatal large tertiary epidemic lower major high respiratory high early respiratory epithelial docu- immunologic related general classic clinical abrupt nonproductive tracheal epithelial runny substernal last more such respiratory subsequent respiratory 5-10 1-4 related nonproductive bacterial viral 0.5-1 young influenza-related excess rapid several most secondary bacterial influenza viral uncommon due Other chronic other chronic pulmonary older cardiopulmonary other chronic recent influenza-associated older influenza- older higher higher older young medical more younger greater predominant high fatal high severe healthy high medical comparable older American annual influenza least pandemic critical public local public federal available characteristic clinical amniotic certain viral demon- additional local individual significant influenza convalescent human specific least fourfold diagnostic clinic antiviral mos 496-1038 1-2 5-14 15-44 yrs 56-110 23-25 45-64 392-635 399-518 125-228 several epidemiological clinical serologic airborne available chronic large infected large upper susceptible direct indirect such influenza most peak tropical documented high-risk 1976-2005 high-risk medical two- major 21- more total primary due epidemic influenza standard previous 5-year epidemic due consecutive available available intramuscular available final available pediatric 0.25-mL available preservative free available multidose thimerosal-free pediatric single-dose thimerosal-free single-dose younger available multidose reduced- free single-dose available “ free single-dose older nºn-commºn same temperature-sensitive cold-adapted temperature-sensitive cold-adapted final residual single-dose other nasopha- least transmitted attenuated cold-adapted temperature-sensitive practical • effective healthy vaccine-induced antigenic effective • effective prior immunologic effective effective healthy younger similar effective effective clinical effective elderly effective effective healthy healthy double-blind placebo- healthy culture-confirmed influenza culture-confirmed Other concomitant antibiotic randomized double-blind placebo-controlled healthy several influenza outbreak greater early effective more influenza 1962-1983 effective old antibiotic fewer severe fewer febrile upper fewer due fewer due fewer antibiotic available other available patient accessible undertaken younger first other most influenza high-risk 6-35 previous older • 6-23 • long-term influenza —pulmonary —renal older least influenza Other such intradermal subcutaneous topical older chronic Other long-term pregnant older chronic • pulmonary such chronic such congestive such • human cognitive other neuromuscular pregnant serious medical immunologic recent influenza-related more second third nonpregnant pregnant comparable nonpregnant high-risk medical pregnant pregnant Available Many protective low protective influenza demon- transient other such pneumococcal other similar clinical serious protective many comparable nonpregnant nonpregnant pregnant many many HIV-infected long-term inmunosuppressed protective essential eligible healthy 6-23 other high own medical influenza high-risk long-term high-risk likely elderly annual other outpatient high-risk healthy younger immunosuppressed severe essential institutional routine foreign previous high-risk current available eligible healthy influenza-related other younger annual eligible available late previous 6-10 previous healthy close high-risk high wild-type high eligible healthy immunosuppressed other Other other Other live specific same simultaneous same such Other live same same least possible Adverse common adverse o-20 common rare previous last Recent systemic common immediate such allergic likely residual current small immediate appropriate occupational other allergic similar medical influenza potential admin- intradermal indicate local subsequent other small difficult rare such annual less true adverse lower severe pre- older medical general low greater greater prudent previous most high severe influenza adverse clinical attributable influenza clinical More approved healthy significant upper such other systemic unpublished significant other systemic reactive 12-59 serious adverse severe chronic medical long-term inactivated anaphylactic other younger reactive other chronic pulmonary healthy higher serious adverse small such rare adverse available such immunosuppressed cardiac additional available high severe allergic severe younger older chronic medical other chronic cardiovascular such renal such long-term other wild-type other live-virus immunosuppressive residual other moderate severe clinical nasopharyngeal deferral adminis- antiviral influenza antiviral antiviral influenza antiviral coolant few visible present frost-free separate dormitory-style refrigerator-freezer frost-free separate 35°-46°F 2°-8°C total first upright dose- second other higher high-risk epidemic-related influenza-related older previous lower black Hispanic non- white fewer high-risk automatic effective high-risk * adverse utpatient other residential long-term acute high-risk hospital outpatient high-risk high-risk necessary unvaccinated other prior appropriate influenza per- high-risk antiviral effective —effective older new active older symptomatic oral uncomplicated older symptomatic more influenza older influenza-related antiviral current general high susceptible inactivated high-risk medical antiviral high-risk protective Other elective uncomplicated new necessary • new i influenza-related influenza-related economic out- economic rapid preventive high-risk rapid preventive weekly sporadic regional less widespread available special available //www.cdc.gov/ncidod/EID/index.htm American live cold-adapted influenza Influenza-associated Available //www.cdc.gov/nip/publications/acip-list.htm health-care Hospital-based pneumococcal asthmatic interpandemic younger prospective healthy placebo-controlled double respiratory syncytial acute pneumococcal other pneumococcal bacterial effective pneumococcal many antibiotic late pneumococcal first pneumococcal first conjugate pneumococcal lancet-shaped gram- positive facultative i Gram-positive short complex important experimental • Type-specific primary antigenic type-specific Type-specific protective pneumococcal other additional serious few pneumococcal common invasive geographic common cerebrospinal younger older common healthy asymptomatic upper military many natural major clinical pneumococcal common clinical pneumococcal invasive pneumococcal short single uncommon Other common pleuritic community- rusty rapid bacterial poor rapid less • higher many pneumococcal community-acquired hospital-acquired common bacterial much higher elderly pleural higher elderly endobronchial young pneumococcal overall high elderly fulminant clinical pneumococcal pneumococcal clinical similar other bacterial nuchal cranial pneumococcal high elderly common common invasive clinical pneumococcal younger invasive invasive pneumococcal younger invasive bacterial younger routine pneumococcal younger highest pneumococcal common middle least Middle ear frequent pneumococcal routine pneumococcal pneumococcal younger significant invasive invasive pneumococcal invasive younger Pneumococcal elderly common common clinical bacterial pneumococcal functional anatomic human high anatomic invasive higher African same American certain racial ethnic particular certain American Indian invasive pneumococcal 2–3-fold definitive other sterile available capsular lancet-shaped suggestive difficult normal pneumococcal white fewer epithelial gram-positive capsular capsular rapid clinical spinal pneumococcal positive large Several rapid pneumococcal other available sufficient invasive pneumococcal other common invasive pneumococcal resistant antibiotic available asymptomatic early human direct person-to-person upper pneumococcal responsible such upper such pneumococcal high common early prevalent pneumococcal unknown pneumococcal More invasive More m 5-17 18-34 35-49 50-64 1998-2003 1-0 preliminary common invasive high 14-valent 23-valent 7-valent pneumococcal nonbacteremic noninvasive overall invasive other sterile highest invasive pneumococcal young younger invasive invasive pneumococcal lowest older pneumococcal young invasive pneumococcal younger prior invasive older young other close Community-acquired pneumococcal sporadic pulmonary pneumococcal common such correctional invasive high pneumococcal pneumococcal capsular different pneumo- coccal 23-valent 14-valent pneumococcal bacteremic pneumococcal cross- several capsular additional available capsular available single-dose 5-dose bacteremic pneumococcal additional first pneumococcal capsular nontoxic younger pneumococcal available single-dose More healthy pneumococcal effective younger most disease poor least effective healthy more pneumococcal certain various clinical effective invasive effective pneumococcal significant underlying effective normal such high severe pneumococcal pneumococcal significant vaccine-type non-vaccine-type more immunogenic healthy high-risk medical effective invasive large clinical invasive effective invasive fewer underwent fewer unvaccinated pneumococcal pneumococcal older older -chronic normal chronic —anatomic functional cardiovascular pulmonary cerebrospinal pneumococcal splenic surgical chronic renal nephrotic such organ = high-dose older asymptomatic symptomatic special social pneumococcal such certain feasible possible 2-week other immunosup- pressive possible complete uncertain unknown pneumococcal same different most single younger high-risk medical primary fourth same other routine separate younger minimum older least older full current least least 24- high-risk medical fewer 24-59 high high highest serious pneumococcal unvaccinated healthy single least older available high invasive pneumococcal other chronic least first high invasive pneumococcal additional last healthy certain higher available pneumococcal substantial improved multiple pneumococcal routine 23-valent older highest serious coccal likely rapid pneumococcal high-risk previous highest severe pneumococcal less highest older functional anatomic multiple chronic renal nephrotic other organ immunosuppressive long-term older second younger first age-appropriate primary common adverse pneumococcal local Local systemic such common fewer severe systemic adverse rare clinical immunologic local severe common anatomic renal —nephrotic rare allergic severe fourth first clinical higher primary most febrile attributable acellular same higher severe attributable pneumococcal severe allergic Such allergic rare severe such upper pregnant adverse high pneumococcal pneumococcal possible coolant pneumococcal few least Pneumococcal pneumococcal older i population-based random-digit-dialed older older pneumococcal chronic high-risk other long-term few More severe pneumococcal few pneumococcal high pneumococcal subsequent high significant pneumococcal American pneumococcal pneumococcal young pneumococcal vac- pneumococcal pneumococcal pneumococcal invasive pneumococcal invasive pneumococcal pneumococcal pneumococcal severe meningococcal first definitive spinal bacterial focal such sub-Saharan meningococcal first major meningococcal aerobic gram-negative several such cytoplasmic several other necessary complement-mediated main serologic distinct asymptomatic groupable invasive relative other such focal bacterial sub-Saharan * gram-negative least invasive other major sub-Saharan further certain pulsed-field elec- useful epidemiologic • small colonized many bacteremic cerebrospinal Clinical meningococcal common invasive L- meningococcal hematogenous similar other sudden stiff other such mental common hematogenous invasive meningococcal abrupt petechial purpuric acute adrenal common meningococcal invasive meningococcal appropriate antibiotic many such —petechial neurologic nº meningococcal common functional anatomic meningococcal genetic such meningococcal upper active passive low higher low likely such higher invasive meningococcal least fatal patient higher meningococcal other similar sterile bacterial low antibiotic cerebrospinal gram-negative meningococcal cerebrospinal rapid specific false-negative common unreliable meningococcal -terminal —concurrent upper socioeconomic -active passive old old 2001:286-688-93 empiric antibiotic clinical meningococcal similar other bacterial empiric broad-spectrum third- appropriate Many effective Few penicillin-resistant endemic natural many asymptomatic most pathogenic groupable direct highest early meningococcal secondary Most secondary secondary general due meningococcal younger highest early early invasive low other young recent different last meningococcal due available due due meningococcal less sporadic Most additional meningococcal meningococcal endemic meningococcal several higher industrialized Meningococcal 1972-2004 1-4 5-14 15-24 25-39 40-64 | Meningococcal 1991-2002 1996-2001 due recent subcutaneous 10-dose vial preservative intramuscular meningococcal current bacterial subcutaneous vac- available single-dose 10-dose Fifty-dose available single-dose sterile 10-dose sterile clear available capsular isotonic meningococcal intramuscular single similar other polysac- pneumococcal effective younger typical independent age-dependent poor younger poor protective younger measurable first single healthy antibod- detectable vaccine-induced likely school-aged least younger more younger older single similar single meningococcal similar least fourfold serum bacte- asymptomatic respective little older single same other different anatomic relative younger highest sporadic short older routine 2-10 available available same other separate separate unvaccinated high Other meningococcal invasive meningococcal high meningococcal acceptable available :1-21 \- meningococcal military hyperendemic epidemic terminal functional anatomic meningococcal acceptable available sub-Saharan dry annual geographic meningococcal —military hyperendemic epidemic —terminal anatomic 54trR-7 :1-21 same other separate separate meningococcal vaccine-preventable probable primary meningococcal less primary more population-based age-specific meningococcal applicable vaccine- other vaccine-preventable meningococcal probable primary Population-based age-specific Such i * older acceptable acceptable asplenic available next present i local such Adverse last 1-2 such i Fewer systemic adverse similar frequent local such systemic severe severe anaphylactic allergic further severe minor vacci- adverse available i Single-dose multidose meningococcal most healthcare invasive meningococcal local sporadic meningococcal antimicrobial oral mouth-to-mouth antimicrobial direct sporadic meningococcal greater total meningococcal higher general secondary highest antimicrobial possible less limited nasopharyngeal helpful preventive effective acceptable antimicrobial chemopro- antimicrobial other other third- other chemoprophylactic Active provisional meningococcal meningococcal young meningococcal meningococcal laboratory-acquired meningococcal meningococcal clinical infectious human Last first Last indigenous intentional susceptible great last intensified global last indigenous global Other large brick-shaped different other other other other aerosolized greater viable several longer low higher such major severe regional oral major severe severe important multiple different other many natural other such first western central susceptible regional asymptomatic further first prodromal small oral characteristic clinical different distinguishable such major severe higher greater major last major first severe many last last indigenous principal clinical major relative clinical ordinary mild flat severe uncommon febrile usual asymptomatic common infectious more smallpox unvacci- nated ordinary prodromal third fourth better red oral ulcerate large cutaneous visible highest infectious few proximal unvaccinated uncommon uncommon infectious mucous ulcerate highest first red skin 2-4 proximal second third third fourth vesicular i central 13-20 pustular 21-28 flattened common other pustular sixth seventh small second third seventh eighth high single particular central same different most more * same more Most centrifugal general clinical numerous severe ordinary-type •Rarely fatal superficial more typical few numerous fatal major Flat flush ordinary-type cer- large severe toxemic extensive seventh eighth flat ordinary-type little umbilicated soft common flat-type most fatal severe uncommon extensive mucous gastrointestinal large Indian pregnant prodromal intense extreme little early hemorrhagic second third other mucous seventh few insignificant cutaneous present hemor- early eruptive flat vesicular soft flat little Most fatal severe mucous overall ordinary flat important other sudden normal other significant such true subclinical major serologic subclinical bacterial most Respiratory eighth viral indistinguishable perivascular due fatal sixteenth clear overall ordinary-type greater less smallpox common due most important other other severe high least Most short severe other additional such abdominal normal important classic different deep superficial uncommon single same more centrifugal several same new several more severe useful maculopapular other febrile such other Other common least limited vesicular adverse recent Other febrile prodrome 1-4 hard same umbilicated rare smallpox- such rickettsial small present hemorrhagic flat-type lethal primary common varicella-zoster viral elderly dermatomal classic regional possible pattern external mucous maculopapular whitish- flat oval peripheral major febrile high low major higher least systemic least additional deep firm/hard abdominal deep same severe same centrifugal greatest distal first oral individual high major sure local possible infectious such high other major more minor high infectious possible low fewer minor available //www.bt.cdc.gov/agent/smallpox/ high clinical probable other other clinical distal oral prodrome classic same major minor minor diagnostic specific acid-based clinical high available other nucleic acid-based such direct moderate important rapid diagnostic infectious clinical predictive positive low smallpox clinical false-positive serious common common false rapid diagnostic important rapid available clinical useful direct anti-VZV sensitive specific dependent careful vesicular rapid clinical consistent diagnostic available least private academic large local Other simplex diagnostic available positive available medical clinical clinical local critical infectious major person-to-person airborne trans- fine airborne negative same other infectious such appropriate disposable other susceptible protective other Reusable such laundry appropriate supportive antiviral antiviral useful therapeutic serious renal off-label other investigational new infec- tious large airborne Most transmission infected natural chronic early global known airborne oral Most direct infected physical viable dried uncommon infectious first infectious first trans- frequent most skin intact present longer frequent general infectious slight high severe prodromal medical unrecognized global next effective low similar highest tropical seasonal evident last early global initial least sur- numerous national epidemic civil other difficult cultural apparent low global Last indigenous enormous last last more particular intensive last difficult few difficult intensive last indigenous additional more last fatal global clinical higher deep-seated same other apparent atypical such flat-type low high high smallpox successful severe rural same same distinct available live infectious current early freeze-dried 100-dose small available effective safe full-strength additional immunogenic additional special bifurcated needle civilian primary primary detectable 1950-1971° < 11-20 125:161-9 available genus-specific cross-protective other detectable primary percutaneous primary higher higher second high primary substantial more high longer greater primary severe fewer vaccinated unvac- cinated secondary lower unvac- lowest secondary less severe primary primary clear Jennerian pustular third permanent major successful major similar primary primary typical other major equivocal several possible equivocal immune viral allergic compo- equivocal incorrect general equivocal possible available available present other such other important severe modified-type Clinical 3-4 5-6 7-11 8-12 primary viral successful major immune viral incorrect military laboratory occupational other other smallpox intentional smallpox non-highly other other such recombinant clinical recombinant recom- public other smallpox intentional initial direct medical public clinical infectious such responsible medical other medical military public successful major routine • military non-highly other other other initial suspected case-patient infectious Other public younger occupational other nonvariola least increased empiric successful old new unvaccinated average average average larger specific clinical bacterial severe mild moderate normal common recent higher higher common constitutional ninth common higher higher | successful Susceptible lymphadenopathy 3-10 —can Susceptible recreational present viral 25-529 23-242 trans- 10-39 frequent primary inadvertent primary common Most specific other significant Most eyelid erythematous urticarial specific rare bullous primary other normal Most normal minor little minor little i limited residual serious i primary severe progressive post- vaccinial least primary frequent older primary life-threatening adverse adverse serious cardiac civilian ischemic localized systemic active severe fatal serious active severe fatal active severe progressive metastatic cellular humoral primary fatal common tle human post-transplant aggressive antiviral primary postvaccinal younger • ſ central nervous such Most allergic allergic direct tº viral nervous complica- permanent specific postvaccinial specific rare primary early early congenital metastatic immunologic cellular Physician-diagnosed rare primary postvaccinial progressive adverse available //www.bt.cdc.gov/agent/smallpox/ severe allergic prior sulfa-type new significant many solid cellular humoral significant immunosup- high-dose higher higher immunosuppressive live other live high last physician-diagnosed such late adverse physician-diagnosed current first pregnant pregnant least close other chronic exfoliative inad- exfoliative chronic exfoliative young other occupational public younger severe same current severe intravenous i available solvent/detergent-treated sterile human healthy ocular high anti-vaccinia plas- effective postvaccinial human severe such eczematous such aberrant other special due effective adverse animal unclear vac- investigational new careful second-line smallpox investigative stable vial early intentional interim local key detailed critical local critical other critical certain military civilian certain overseas general other critical certain high certain overseas general public diluted smallpox vaccinia-naïve military biological medical public national statewide national new temporary sunº zoonotic black biblical Indian human contagious first microbial first live animal live human cell-free cell-free large aerobic spore-forming gram-positive common such long viable infective many potential direct sufficient such proteins—protective lethal lethal responsible biblical responsible aerobic viable clear extensive mammalian mucous intracellular antiphagocytic lymphatic large widespread organ mediastinal effective vegetative extensive massive characteristic inhalational cutaneous alveolar lymphatic effective vegetative effective nonvegetative therapeutic numerous delayed gastrointestinal clinical —cutaneous common i natural clinical cutaneous rare human cutaneous other cutaneous small pruritic necrotic characteristic black Other adjacent cuta- neous initial cutaneous antibiotic antibiotic intestinal regional lower acute abdominal gastrointestinal unknown common intentional median first bioterrorism-related several non- productive 1-12 necrotic black 1-7 cervical abdominal • 1-7 radiographic mediastinal antibiotic antibiotic clinical pleural PA-based bioterrorism-related prodromal high pleural due case- intensive similar early other other such runny common common common common Most chest most abnormal primary secondary bacterial cutaneous characteristic black vesicular typical gram-positive difficult other severe gastrointestinal typical difficult useful clinical bacterial great advanced visible unspun peripheral Gram-positive other clinical such pleural oropharyngeal cerebrospinal positive Other pleural PA-based specific capsular important therapeutic sensitive several oral antibacterial such resistant other such bioterrorism-related antimicrobial active previous apparent antibiotic therapeutic previous intravenous least other active intravenous oral aggressive such pleural acid-base mechanical cutaneous first-line cutaneous systemic extensive simultaneous cutaneous cutaneous current additional active –30-60 cutaneous gastrointestinal communicable rare cutaneous other animal rare Biological common agricul- tural rare human main resistant physical many dormant certain common direct cutaneous such important undercooked airborne industrial larger difficult able smaller small lower animal rare other laboratory-associated animal rare effective contagious cutaneous rare most anthrax-infected anthrax-contaminated true human difficult unreliable largest recent human annual human early Most cutaneous single cutaneous 20th recent domestic animal single other intentional 1951-2004 un veterinary live veterinary cell-free human cell-free other cellular small preservative direct compatible cutaneous gastrointestinal other least supportive compatible alternative compatible environmental corroborative local first live live unencapsulated principal veterinary occasional unsuitable early 20th first human minimal short-term human protective protein- free FDA-licensed human cell-free fil- m u dead cellular more responsible detectable fourfold anti-PA clinical alum-precipitated PA-based cutaneous available younger older protective alum-precipitated several animal different human protective unknown animal subcuta- neous cutaneous unknown high intentional certain military annual annual other entire extra six-dose primary local intramuscular subcutaneous similar high clinical low other high certain military other select intentional first federal medical private available nonhuman post- protective effective current optimal human vaccine-induced more fourfold clear nonhuman sufficient common adverse local minor local less moderate local severe local more Local several multiple systemic common rare several due local more injection-site effective effective animal PA-based current FDA-licensed various doxycycline severe significant adverse few short-term 25-year unusual unexplained life- adverse general long-term adverse possible several scientific available younger older high specific local systemic available severe anaphylactic allergic severe adverse severe severe adverse low-grade potential potential related adverse necessary suboptimal demon- such effective effective non- human other less similar former lethal initial Such inadvertent biological more • third inhalational pregnant 10-15 likely biological stable high antibiotic possible antibiotic antibiotic suscepti- antibiotic susceptible minimum attainable oral potential antibiotic available standard 3-dose effective subsequent additional cutaneous gastrointestinal rare gastrointestinal possible current expert clinical antibiotic prolonged least offensive biological many least unknown likely biological high greater other potential biological other cutaneous postal direct Most several direct contaminat- Several i antibiotic available i intentional interim public bioterrorism-related interim antimicrobial bioterrorism-related human systematic biological safe //www.cdc.gov/nip/recs/child-schedule.htm Spanish black white 4-page 2-page accessible Downloadable commercial //www.cdc.gov/nip/recs/adult-schedule.htm black white 4-page 2-page commercial accessible last adolescent 13-14 g L.- 1.- Yearly routine subsequent feasible special other respective significant adverse available 800-822-7967 old º- º-3 unknown possible HBs.Ag-positive possible HBs.Ag-negative rare original HBs.Ag-negative laborato- medical vac- second final permissible positive next well-child acellular fourth early third unlikely final acellular 11–12-year single primary final least first second susceptible reliable ceptible least Meningococcal old unvaccinated high Other formeningococcal fresh- meningococcal acceptable invasive meningococcal terminal anatomic functional certain other high RR-7 acceptable pneumococcal certain final certain high-risk certain limited cardiac human other high 2005:54|RR-8 healthy healthy influenza-related healthy acceptable intramuscular vac- least least least new routine 1-year-old certain high American • More minimum first final first current necessary final final 12-14 current second further first previous final first necessary 2- currentage-24 final final current healthy previous healthy first first current necessary fourth fourth first third final least second necessayſ third primary catch-up last further 2-dose susceptible CATCH-UP all-IPV all-oral fourth current 3-dose adverse federal 24-hour national toll-free vaccine-preventable local additional 800-CDC-INFO 800-232-4636 º 1-dose 4-8 populations- more other medical occupational other recommended medical other complete significant available 800-822-1967 available 800-338-2382 available 232-4636 chronic pulmonary elective terminal chronic brospinal long-term 1-dose 6-12 6-18 dose -º-nu- 1-Z dose 1-2 other present medical occupational other prior American º- second last American second single full pediatric tetanus- diphthema-acellular available 2005-SEPTEMBER uncertain complete primary toxoid-containing primary least third immune medical second unknown postsecondary educational other measles-containing severe laboratory unreliable child- pregnant pregnant high severe high young institutional correctional military nonpregnant international age-appropriate least parental typical non-U.S.-born atypical typical acute labora- pregnant pregnant chronic chronic renal cognitive other neuromuscular severe secondary severe long-term other long-term high in-home high-risk -a-rº- ºvic-s special 20-19/ml 0ccupational other allied previous Other chronic comectional international high chronic anatomic functional Other first-year military meningococcal hyperendemic epidemic sub-Saharan dry local annual acceptable high epidemic available older chronic good healthy nonpregnant special chronic pulmonary chronic renal nephrotic functional anatomic sickle elective least immunosuppressive congenital immunode- close possible highest multiple generalized high-dose long-term Other certain American Indian other long-term pneumococcal chronic nephrotic functional anatomic sickle immunosuppres- sive marrow high-dose long-term one-time primary chronic illegal Other high intermediate 2-dose * American dose next next dose 1-4 1-4 2-17 6-18 6-12 15-18 influenzae Hib-2 Hib-4 12-15 IPV-2 2-14 IPV-3 6-18 IPV-4 4-6 Pneumococcal PCV-2 PCV-3 PCV-4 12-15 MMR-134 12-15 4-6 º 12-18 tº 12-23 6-18 18-41 6-10 acellular acellular available separate equivalent American minimum oldest individual minimum equal greatest individual available less old other least least least first older fewer older pneumococcal young old younger older first congenital RR-8 older least younger old first younger first younger influenza older second meningococcal high meningococcal second acceptable RR-07 previous previous tetanus-containing second highest serious pneumococcal likely rapid pneumococcal previous highest severe pneumococcal younger pneumococcal other catch-up other related long monovalent previous revious anaphylactic 1-2m final last dose |-3-dose single-antigen 4-wks severe acceptable least 0- 2-4m 0- 1- HBs.Ag-positive newborn special 1-2m interchangeable 3-dose unknown dose 1-2m unvaccinated positive give 2-dose routine 15-18m early early unlikely preferable mandatory same anaphylactic •Previous ous least severe serious previous higher continuous limp previous progressive dose anaphylactic last older severe previous toxoid-containing early least Previous anaphylactic neurologic older certain severe website www.cdc.gov/nip/publications/ACIP-list.htm sure current puupa-utelluno uo uwoux u un uelnosewoſpjeo uo uoplosip uoquo uo uomoeau onorſkudrup snowola- unuo，o uonnesouri uomocou uopeoſ uosmºs portuose nun upou uomon abu- usnje sxw9-tº uo uoſinciunului diovoos ºsop-ų3ų uo ui uoauº uinqol3 il- uuºu-ſºuoſ uiuuw uomocou uÁI oous uomiº upo uo uoauð uovououw uomiº pinous uoud-ſunuupuo uppuauuuuo ui uoaſă uo sumuul il- uºlų uomocou smolaoui- uomeopuſtinuo， unuo，o uomensiuņupe plnous uopſo plnous uoðunoſ uopliųo uzi ueųı uoºunoſ uouplių， suae-ç uopio uoupių： jo tuçç-9 unupiųo owo-10 suÁó-tuº sosop owo-ºžinių| ººr lugz-oplių， ºut- su-it uo owul- auto-oſuolųo un uſz-9 out-| uapuqo un uolųn uo uoaſº uso unuiuuuuOs uuşl-z usoop uuzl uovº uoluno uoaſă suÁ9-t ne |- uusi-zi aalo-|- uou uo uouº ºpç-ſ uoluſ uopſo uuzl uoupių： uta •āt uusi-zi ubauð upo dn-ųomeo uou uoſ uæquo uopeupora uou upora uuuuooº catch-up other other mild anaphylactic |- unvaccinated last previous interchangeable different previous severe necessary primary older least dose dose • |-Dose early younger anaphylactic unvaccinated healthy com- least unvaccinated high-risk 7-11moſ give older previous severe acute next High-risk sickle anatomic/functional previous pulmonary renal least least previous anaphylactic least final high-risk com- older older dis- functional anatomic least previous severe least anaphylactic older older severe previous -Live local -Wish high ococcal anaphylactic neurologic older younger older diphthe- functional terminal meningococcal hyperendemic severe acute younger Other meningococcal optimal annual other influenza mild anaphylactic severe anaphylactic other chronic pulmonary medical such renal hemoglobin- immune defi- severe acute one-time previous unknown -One-time high- fatal pneumococcal inſec- rapid renal older previous anaphylactic severe older medical influenza cognitive other neuromuscular at-risk pregnant other direct at-risk out-of-home current essential other institutional influenza non-pregnant younger at-risk other direct at-risk out-of-home current essential other institutional older other chronic pul- monary chronic special social certain American fatal pneumococcal anatomic immunocompromised multiple chronic renal nephrotic immunosuppressive specific official 23:2-4636. www.cdc.gov/nippublications/ACIP sure current more informa- least mild thot anaphylactic severe older minimum •Give primary anaphylactic severe • potential contraindica- anaphylactic severe previous toxoid-containing unvaccinated primary 1-2m 6-12m previ- unique sched- High-risk renal certain healthcare public long-term correctional certain interna- tional chronic endemic HBs.Ag-positive first same susceptible complete chronic illegal experimental medical private effective likely effective older younger certain high primary sure early receiv- previous ous new late older primary expo- sure wild-type likely endemic anaphylactic severe acute • contraindica- Þ |- E- ！w s√≠√∞-t-| uomiº upis uulnouºqni uoneopunenuoo |-Ili un uo ui uoană uſinqola low uone （sop-qºrq ununul uomocou ucun uo u uouſow uomiº pinous uoneuropea uotuow usuwow uuoq own pinous qånų-isod usquio uomocou uoueorpuſe uolue ut u u u^ 11- naissoid ºsop-iſºmų uo uondºpenuoo uuni oubyen uſonovaj nou uo ourooeae op sºwº-ruow ubanº （su-qduq ui uo ubatº plnous n uſoq uloq ºsminioau （ſºunt-oxi uostºs|- ucuruſes-qns uſoq upiųw uſ uu low noºleºnſuoo sºlopv-lebboso una uneluopun uodau ulºs uſ uolue ut uſ ørow…os pue|- pinous u uoneuroopa low º- immune different monoclonal negligible Whole 80-100 intravenous maximum syncytial immune 300-400 immune entire additional immune syncytial asymptomatic symptomatic other immunosuppressive 3-dose dose anti-HBs serologic prior primary 3-dose on-the-job fecal 3-dose 0- 1- 6-month least ml positive ml negative unpro- 3-dose positive —If negative consid- susceptible probable parenteral possible per- positive positive Anti-HBs original expo- anti-HBs negative non-preg- nant healthy younger annual out- immunosuppressed protective medical desirable equivocal appropriate first more least live least live acceptable rec- unvaccinated reliable effective commercial sensitive vaccine-induced 3-dose primary tetanus/diphtheria-containing necessary acellular unavailable accept- able recom- additional specific official state- www.cdc.gov/ nip/publications/ACIP-list.htm X-linked humoral variable immune live severe effective selective Other live safe ineffective complete live * humoral immune Wiskott-Aldrich ataxia- early effective late effective granulomatous safe effective secondary safe effective routine bacterial viral yellow chronic granulomatous inactivated effective effective effective routine bacterial viral yellow bacterial 71-72 1-18 – B-1 B-4 B-14 primary diphtheria 4-dose 3-dose Act-le 4-dose pediatric vial 6-35 prefilled Intra- viral Japanese viral viral viral viral viral viral bacterial bacterial 11- bacterial bacterial viral viral viral viral bacterial bacterial toxoid bacterial bacterial viral viral taneous viral inactive necessary pharmaceutical vac- other immunologic suitable further pharma- ceutical reasonable manu- human oral green residue Ethylenediamine-tetraacetic residue preservative solvent nese oral most most oral residue Japanese cellular residue antibacterial red phenolsulfonphtha- most most glycol p-isooctyl- viral inacti- nonyl viral inacti- solvent Yellow multi-dose contain- precise tidose Japanese single-dose stable unspecified combi- fertilized Yellow YF-Vax Stainer-Scholte con- extract green Japanese meningococcal fetal DTaP-Hep Synthetic/semi-synthetic thi- joint 1999:48:563-565 1387-92,1397-1401 harmful preserva- 112:1394-1401 unspecified 2-Phenoxyethanol 2- 2-Phenoxyethanol 2-Phenoxyethanol | 2-Phenoxyethanol cº-Tocopheryl multidose p- multidose 2-Phenoxyethanol 10-dose unspecified Ethylenediamine-Tetraacetic 2- unspecified 2- oral refrigerator- stable Ethylenediamine-Tetraacetic equivalent thimerosal-free biological additional individual single adult/pediatric preservative free preservative free _multi-dose preservative free 2005-6 multi-dose single decreased equivalent thimerosal-free post- biological dose dose dose |DTap-Hb = spack-1 dose |Hepatºse-Hibº dose dose dose dose |- dose dose- dose 11-15 Hib- |Hib- spack-1 dose dose pack-1 dose dose dose |-vaccine dose preservative dose dose dose dose dose preservative s1070 –– preservative free dose dose many international Vaccine-Related many foreign English many Vaccine-Related Russian difficult international unified Several Indo-European Western European available comprehensive complete many international complete acellular acellular whole whole whole Chemo-Sero-Therapeutic whole live military human immune human 1987-1989 whole live yeast Chemo-Sero-Therapeutic live military pediatric acellular acellular acellular generic acellular generic recombinant whole Tick-borne whole whole whole recombinant plasma-derived live 1969-1979 live 1970-1973 acellular whole whole inactivated whole live live live live live whole whole live generic live live live live live live live live live generic generic whole oral whole oral oral pneumococcal 7- acellular acellular pneumococcal 23-valent 7-valent 7-valent live 1959-1968 syncytial generic live live live generic live live generic oral live live oral injectable live immune immune generic oral acellular acellular acellular live acellular acellular live oral live live pediatric live oral parenteral injectable parenteral live live live injectable live oral p. oral live generic live live North American many complete Serbian p. Spanish Serbo-Croatian Japanese p. German German Serbian | German French rengkong Spanish Japanese German Norwegian Spanish Spanish convulsive Spanish Serbo-Croatian Indo-European Western vial multidose earliest vial p. frozen vial manufacturer-filled vigorous Single-Dose Manufacturer-Filled Special earliest sanofi vial vial frozen earliest insulated vial Single-Dose frozen earliest vial manufacturer-filled frozen vial vigorous Special earliest insulated frozen vial vial Special earliest ºt- frozen current vial earliest dry white red further own exterior frozen manual frost-free necessary Careful necessary frost-free new 2005-2006 2004- current impenetrable Special earliest live dry dry less entire total warm such dark earliest live º frozen frozen vial white clear vial earliest intramuscular single-dose 10-dose multidose 10-dose frozen vial homogenous white vigorous Special vigorous insulated frozen vial multidose severe local p. dry dry present frozen separate last standard Dormitory-style appropriate necessary Careful necessary other 1-800-609-4618 earliest live * 800-822-2463 alº-ara 800-288-8371 drug-service 404-639-3670 medical 866-475-8222 general 800-666-7248 n-Irber eithe Househºld-style corrirre-cla-style d-ºrrito separate o- uſes so-ºat longest shortest soonest reſrae-a-or extra rainian other Ice-filled clinic next manufac- waſ 1-er local unt= crºciz cº-ºchk least monthly earliest large stable open electrical electrical perishable immedi- auxiliary other local | electrical electrical electrical critical clinical practical general supervisory professional American state/agency-related competency-based active Many other available inaccurate misleading other reliable open safe informed multiple important health-care uncomfortable subjective multiple individual previous important vapocoolant non-aspirin-containing age-appropriate Age-appropriate non-pharmacologic separate next single effective good alcohol-based antiseptic mandatory vaccine potential open important needle stick appropriate follow-up state/local accidental needle medical critical separate parenteral engineered available many needle stick potential clinical optimal needle viscous fine 22-25 Needle-free new needle-free needle stick health-care needle-free last lyophilized entire needle necessary possible equal | vial needle vial positive allow single entire vial excess difficult Other possible other immediate large few few clinic immediate live unstable identifiable partitioned imperative appropriate severe local adverse adequate adequate 1-2 adequate live upright 6-35 deltoid young 23-25s posterolateral upper young cal upper young upper adequate 22-25s 1-2 i- young able Posterolateral upper young upper 23-25s 2-dose sof adequate 1-2 nº complete particular www-rº-'ra- usual thigh upper necessary upper 5/8-inch 23- 25-gauge needle appropriate circular light several dry several lateralis anterolateral upper > femoral _-Sciatic intramuscular middle femoral older deltoid adequate 22- 25-gauge needle needle adequate typical various 7/8- 1-inch older 7/8- 1/4-inch 1- appropriate circular acceptable pediatric geriatric needle light several dry new entire multiple same more same 1-2 local maximum same deltoid same necessary acceptable different specific familiar other similar 23- least • vial natural severe anaphylactic rare local individual necessary primary health-care • vasovagal vasovagal allergic supportive Y-II life-threatening allergic initial current detailed medical allergic rare 15-20 permanent medical common lower lower right state/local complete available self-assessment annual perfor- new iden- probationary annual self-assessment medical several appropriate private corrective appropriate safe effective pediatric probationary proper clinical safe effective special comfortable applicable medical clinical up-to-date vial aseptic |- ：-（ |- i===|-i unu voºr-º º-warae usuz •maeo|- paſſwouppy unuou-ſ uonoe ue uºquo unwa unwa uonuºu uomensluupe uo upewa uaqſo uo uonbos nuð， uedoud uonov upeº uºuuq uºqae |-|-ºmep un uomezunuuuu upeo （aunpºpold uopuuoo uºuenuoosdeus （9|- upeº uo uºpuo nuºussºssy p. 1-12 22-25mm 22-32mm 25-32mm unuuuu ºsoidoo uo- |-|-|-： |º |- |- uo steady other other e-c p. federal current recent 3-month-old vaccine-associated paralytic first sequential live current serious many Most adverse self-limited such rare re- ef- safe possible important parents/legal ob- jective dis- ad- common mild vac- standardized objective infor- adverse un- and/or informa- state- prop- minor legal address con- parent/legal repre- mandatory pneumo- coccal vac- available pneumococ- cal yellow vac- re- federal meningo- coccal local individual other legal NCVIA-covered tered parent/legal representa- current available patient n-ºn- objective jour- ap- imperative current Most current recent available local available several complete current effective pneumococcal current legal such such relevant legal long-term single other quali- minor visual oral permanent medical permanent medical legal additional applicable camera-ready available available §300aa-26 available other current available single hard new available Spanish compatible available more French Armenian German Laotian Serbo-Croatian Bosnian appropriate informed tear-off technical infor- enough procedural oral substantive medical informed appropriate legal same legal legal other legal legal representative sure representative adverse new final new adverse previous new visual oral unable least compatible available old obsolete adverse multiple identical different recently-dated valid current adverse clinical likely p. traditional difficult standard reliable multi-syllable understood individual long easy useful several low racial ethnic available meningococcal available own own other other prior legal present school- adolescent legal medical permissible single entire acceptable first legal complete possible approximate future additional initial legal original additional earlier next original additional medical additional additional significant adverse earlier adverse previous medical main -vis co- explaint-v-ºne legal certain new other format recent Last updated main ºwed- adºes- other lſanthrax printable screen-reader screenreader- unawanassanum accessible printable aerº-sº ext-ºnly spanish printable type Reportable F-2 national most describe such serious such important new Most other adverse significant adverse such unsure next adverse pre-addressed 1-800-822-7967 printable more e-mail toll-free toll-free anaphylactic applicable additional iºcese anaphylactic applicable additional |- anaphylactic applicable additional applicable additional vaccine-strain viral applicable additional p. viral applicable additional anaphylactic additional applicable anaphylactic applicable additional additional additional applicable additional iºcese additional Reportable reportable 300aa-25 significant unexpected certain adverse anaphylactic severe lethal systemic Most few laryngeal cardiovascular other peripheral single peripheral central spinal nervous deep severe upper upper notable clinical such applicable such severe associated least follow postictal older least least significant mental confusional independent intracranial clinical clinical least greater absent painful other absent external familiar clinical sig- nificant mental high-pitched unusual inconsolable other first applicable least vaccina- normal neurologic encephalopathy residual neurologic subsequent chronic secondary genetic chronic encephalopathy metabolic structural genetic bolic structural genetic chronic continuous more Medical chronic such connective limited systemic systemic mixed connective fibromyal- infectious other direct immune metabolic dis- neuropathic joint joint chronic invasive sterile clinical invasive radiographic positive invasive bacterial Reportable 1-877-721-0366 Toll-Free 1-800-822-7967 Last Responsible different adverse diagnostic other Other office/hospital clinic physician-diagnosed medical adverse applicable 300aa-25 other voluntary ltern SPECIFIC suspected adverse Such local general same possible more adverse serious negative normal relevant abnormal other separate best essential possible such Reportable other serious other adverse adverse legal adverse 09-20-0136 legal available available legal same short pre-existing physician-diagnosed medical adverse previous more prior additional old no-fault traditional compensible individual vaccine-related medical special eligible special Compensable non-compensable civil peti- p. toxoid-containing anaphylactic 0-4 2-28 applicable il anaphylactic 0-4 applicable anaphylactic 0-4 5-15 applicable |W 7-42 applicable w 7-30 applicable live non-immunodeficient 0-30 immunodeficient 0-6 applicable viral non-immunodeficient 0-30 immunodeficient 0-6 applicable applicable anaphylactic 0-4 applicable antigen-containing anaphylactic applicable applicable applicable applicable live oral rhesus-based 0-30 applicable applicable new applicable routine nasal p. anaphylactic severe lethal systemic allergic few cardiovascular Other significant clinical lower minimal spleen significant such applicable such more associated least postictal older least significant mental confusional independent intracranial clinical clinical least greater applicable painful other absent external familiar clinical significant mental high-pitched unusual inconsolable other first neurologic applicable least normal neurologic encephalopathy residual neurologic subsequent chronic secondary genetic prenatal perinatal fac- encephalopathy metabolic structural genetic metabolic structural genetic vaccine-related possible preponder- encephalopathy shall- entire medical myoclonic tonic-clonic grand complex partial chronic objective continuous more chronic such connective rheuma- systemic systemic mixed con- nective vascu- infectious other direct immune metabolic neuropathic inflammatory joint chronic upper other peripheral single peripheral central spinal nervous deep steady severe shoul- upper weak- upper notable clinical present same opposite bilateral upper physical electromyographic consistent attributable brachial distinguishable con- peripheral other peripheral central nervous cranial less Thrombocytopenic other such previous lymphoproliferative hemolytic uremic viral intravascular bacterial viral human antecedent viral clinical sero- logic normal normal Vaccine-strain viral specific monoclonal Vaccine-strain viral vaccine-strain sufficient specific Vaccine-Preventable 1950-2003 G-1 20th 1962-2004 1950-2003 paralytic reportable other other invasive notifiable 1971-2002 Reportable 1950-1970 respective paralytic 1900-1998 p. 1962-2004 measles-containing more measles-containing more measles-containing represent 2- year-old represent 19-35 month-old national recent 19-35 1133-7. available p. H-3 H-5 H-14 public private local public private essential desirable medical public important national vac- cine-preventable several important private primary critical such national preventive high important experience- ready vaccine-related inaccurate many American federal local professional 2001-02 medical public H-3 inclusive many clinical mid-level physician medical clerical useful public profes- desirable current difficult little best clear necessary own adoles- feasible likely available other possible Effective appropriate easy-to-understand appropriate accessible knowledgeable receive on-going many pos- complete accessible adverse aware separate due overdue Office- clinic-based per- community-based available main such physical necessary other possible comprehensive primary routine other other subsequent primary primary iden- well-care age-appropriate educational physical important sufficient available easier p. Out-of-pocket costs-including fees-should low possible low possible Free available public reasonable local aware setting-private covered high preventive due medical prior adverse available available www.cdc.gov/nip/recs/child-schedule.htm other relevant medical Effective appropriate sufficient hand-held adolescent federal vaccine-specific necessary oral other appropriate adolescent adverse medical necessary 1-800-232-0233 Spanish latest available numerous other www.immunize.org national appropriate appropriate available local available 404–639-8222 accessible safe effective vac- adverse consistent up-to-date knowledgeable receive knowledgeable receive adverse other other specific responsibili- distance-based satellite web-based self-administered available many possible same American safe effective certain simulta- neous earliest simultaneous accurate complete accessible accessible medical rapid federal 300aa-25 medical primary primary local available complete useful new hand-held pro- available adverse aware separate significant adverse certain adverse medical possible aware no-fault aware separate 1-800-822-7967 available 1-800-338-2382 other available due overdue due overdue specific high medical previous intensive due overdue other automatic clinic-based effective low local community-based highest possible vaccine-preventable entire opti- vaccine-preventable high underserved Community-based public other such Special serv- p. 19-35 20:28-31 21:243-249 free physician public medical 184-186 available American www.health.gov/healthypeo- Physician School-Based infectious adverse public private local governmental ex-officio valuable available American H-23 successful vaccine-preventable similar older younger high older younger high pneumococcal susceptible routine vast vaccine-preventable average influenza other invasive invasive pneumococcal due young unpro- congenital safe effective available high certain racial/ethnic pneumococcal comprehensive nationwide vaccine-preventable dramatic current pneumococcal older annual pneumococcal national less high due medical behavioral environmental greater professional private specific nontraditional recent comprehensive previous evidence-based possible available personal desirable major professional public private neces- sary useful current additional available available valid available simultaneous accessible due overdue Regular Patient-oriented community-based available recom- vaccine-preventable recommended meningococcal international physical additional educational mate- appropriate patient/guardian con- sufficient patient low possible older patient private vacci- basic new initial annual medical certain preventive pneumococcal valid invalid prior adverse current valid invalid valid native possible public private available other profes- ample available medical sched- adverse consistent CDC-recommended available significant adverse follow- medical aware encour- available 1-800-822-7967 p. no-fault compen- aware available 1-800-338-2382 separate Such brief adverse other public other medical more individu- simultaneous indicated safe effective Simultaneous adminis- combined pneumococcal same separate safe effective accessible accessible loca- medical unnecessary medical such influenza paper-based personal medical modifiable available available other first annual appropriate vaccina- available due overdue due overdue specific high med- intensive individual due overdue other specific general available available other insti- tutional enable non-physician such direct physician administrative such physician available Regular such per- other local available available Patient-oriented community-based exam- other such other profes- local 1-28 syncytial invasive pneumococcal antibiotic 1995-1997 invasive 1995-1998 285:1729-35 1993-1997 greater equal 532-3 |- Vaccine-Preventable 725-729 1133-7 1-13 Vaccine-preventable vacci- Physician American School-Based infectious adverse public private vac- local repre- governmental ex-offi- valuable public many professional social vital easy public much harder public important public public public governmental public other public voluntary community-based other public essential public essential several national federal public public essential public overall public common public physical mental ten public public valuable promising essential general public specific programmatic com- good other critical public public major public essential essential public public broad personal healthy individual personal unavailable public personal per- population-based new innovative preventable major safe available Several low inadequate aware- medical public private federal major public major clinical financial public private vaccine-preventable dis- vaccine-preventable new prac- international many infec- tious ” disap- whoop- indig- enous few congenital ru- sel- re- extraordinary attributable widespread congenital syn- able constant un vaccine-preventable strik- fewer vaccine-prevent- able compari- influ- pneumococcal hepa- many child- vaccine-preventable young major such Vaccine-preventable main important costly American several ad- much heavier ex- per- general vaccine-preventable signifi- cant effi- several immuniza- selective universal different different individual forchild- child- statutory communi- few private ne- private in- expensive free most full public avail- responsible high best diffi- same new pneumococcal vac- many new ini- American fectious next influenza cost- vaccine-Preventable -99.7 1964-1965 available provisional vacane-associated reportable reportable Table Tetanus-diphthena 40- appy older potential additional annual different * Japanese yellow apolicable adultim- de- Vaccine-preventable significant strong cost-effective un- prevented less first general high-risk immu- pneumococcal new under- able clinical good organiza- vac- specific de- successful regular public se- vaccine-preventable essen- elderly severe pneumococcal young sexual ac- Many un- clinical public immuniza- admin- helpful older educa- tional other wide- rec- riodic immu- better understand- administrative organiza- tional successful profes- prac- tical vaccine-preventable dis- ben- easy vac- recom- educational espe- announce- popu- efficacious effective local public federal con- epidemiol- vaccine-preventable pro- ditional regulatory private im- sufficient subject gov- Similar reimburse administra- moni- iden- tified technical financial other private providersfor indi- vidual cov- 18-24 25-64 special occu- able Such vaccina- several mis- vac- vaccine-preventable due vac- high Most ad- wide principal general spe- profession- administrative such such single respon- dif- devel- workable Such common other federal vaccine local com- provid- administra- tive organizational regular stan- regular evalu- financial federal local pneu- mococcal local unpublished pneumococcal vacci- elderly reim- end- renal influenza reim- pneumococ- cal pneu- mococcal pro- adequate important annual influenza little ex- private adultim- organi- such bet- tra- public wºocºne-prºtebºe insured national pro- immu- vaccine- preventable continu- them- capac- periodic vac- effective efficient vac- clear un- epi- important per- local vaccine-preventable ex- timely ad- current ” under- hepati- pneumococcal inexpensive rapid essential economic vac- cine-preventable immuniza- constant pro- economic vac- es- costly pneumococcal elderly pneumococcal little geographic great vac- other high-risk more surveil- vaccine-preventable local better recom- current future peri- potential technical regulatory financial legal political appropriate federal related specific high-risk condi- specific pro- un- fol- pneumococcal institution- ill older least pneumococcal influenza non- high-risk least high-risk antigen-positive least work- least intravenous-drug us- least homosexual least50 bac- essential new vac- important vaccina- older immune responsive initial ef- clinical serious costly economic vaccine-preventable dis- im- cur- pneumococcal effective other pre- inter- common elderly epi- vaccine-preventable vac- greatest likely several new cold-adapted live pneumococcal acellular new newer epitope-based re- rec- immunologic vaccine-pre- ventable other international such supple- infectious such former new antimicrobial-resistant many coun- rich eradi- new be- new direct new continued microbiologi- vac- alternative 1990.263:1218-12 Pneumococcal poly- cur- 1993270:1826-1831 48-56 79-81 1986,140,528-630 Comprehensive 1986-1992 Russian 1990- toxigenic 501-503 drug-resistant pneumococcal 1994.271:1831-1835 * cal vaccine-preventable immunocompromised de- better economic cur- future vaccine-preventable dis- immuniza- evi- current fu- recom- greater stud- new stable com- greater federal nongovernmen- tal professional associa- interna- tional Gen- eral recommen- teta- other Eradi- 10222-229 1989- 1992,43:451-463 congenital univer- 1989,84779-784 in- 1987-1993 Reportable vaccine-preventable 43:57-60 1993.328:1252-1258 medical set- em- sub- stantial immuni- less op- timal infectious im- optimal adverse responsible non- produc- Na- Schaff- im- elderly 1532.105-2111 public preventable Infectious demon- 1988-1992 pub- pneumococcal elderly 1992:8:183-199 influ- enza I-1 I-2 I-3 I-4 I-5 I-6 I-7 800-232-4636 800-CDC-INFO Spanish vaccine-preventable single vaccine-preventable related e-mail //www.cdc.gov/nip such online latest downloadable other //www.cdc.gov/nipſed/curriculum/curric-brochure.htm online online viral reliable helpful informative current periodic several immunization-related • toll-free global international ready-to-print educational Other other professional most federal viral * ==- many other useful free old //www.immunize.org/catgidſp4060sor.pdf is- 11-19 much practical e-mail new new hot • vaccine-preventable e-mail Subject _- en-uºulºn f 35-minute latest Available Spanish different Other payable | 594-2 other global national other immunization- Global //www-nt.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm routine Little PSD-IMM-A4 206-2044 562-7802 364-3276 661-2300 883-6015 691-6118 509-7945 739-2358 657-1463 586-8302 334-4914 524-0967 746-6388 Chavez-Torres_M 233-7805 ] 50319-0075 66612-1274 831-6292 296-6368 564-4760 483-1909 287-8127 333-5893 Talebian 335-9855 676-5689 Vaccine-Preventable 08625-0369 576-7686 526-6892 444-2920 471-6426 684-8338 271-3850 588-7431 827-2898 I-10 12237-0627 27609-3811 58505-0200 10th 474-7381 676-2252 870-4824 328-1412 728-4279 271-6133 @ 731-3095 |- 685-6806 222-1442 898-0318 773-5509 458-7288 794-9937 207-8882 538-9440 lable 25301-3715 865-7701 786-0396 235-3590 576-6418 558-1941 267-94.93 @ 777-6001 Wells-Fahling 011-684-633-7223 011-684-633-5379 011-671-735-71.43 011-671-734-1475 .248-4393 011-692-625-8457 011-692-625-3432 011-691-320-2619 011-691-320-5263 011-670-236-8733 011-670-234-8930 011-680-488-4804 011-680-488-3115 I-14 appendir 274-5619 777-8762 